natgillin/translations-raw huggingface dataset:
children aged 2 to 5 years with beta thalassaemia major who receive frequent blood transfusions, when deferoxamine (another medicine used to treat iron overload) cannot be used or is inadequate;
otrocih v starosti od dveh do petih let z beta talasemijo major, ki pogosto prejemajo transfuzije krvi, kadar deferoksamina (drugega zdravila, ki se uporablja za zdravljenje prenasičenosti z železom) ni mogoče uporabljati ali ta ni ustrezen;
Children aged 2 to less than 12 years and teenagers aged 12 to 14 years weighing less than 50 kg
otroci, stari od 2 do manj kot 12 let, in najstniki, stari od 12 do 14 let, s telesno maso manj kot 50 kg
Children aged 2 to less than 12 years: The daily dose in children depends on their weight.
Otroci, stari 2 do manj kot 12 let: Dnevni odmerek za otroke je odvisen od njihove telesne mase.
Children aged 24 months – 5 years: one single dose.
Otroci, stari od 24 mesecev do 5 let: en sam odmerek.
Children aged 3-11 years must take the content of one jar for one test.
Otroci od 3 do 11 let pri enem testnem postopku vzamejo vsebino enega lončka.
Children aged 3-9 years
Otroci, stari od 3 do 9 let
Children aged 6 months to 5 years:
Otroci, stari od 6 mesecev do 5 let:
children aged 6 to less than 12 years
otroke, stare 6 do manj kot 12 let,
Children aged 6 to less than 12 years who weigh from 17 kg to less than 22 kg:
Otroci, stari 6 do manj kot 12 let, s telesno maso od 17 kg do manj kot 22 kg:
Children aged 6 to less than 12 years who weigh from 22 kg to less than 28 kg:
Otroci, stari 6 do manj kot 12 let, s telesno maso od 22 kg do manj kot 28 kg:
Children aged 6 to less than 12 years who weigh from 28 kg to less than 35 kg:
Otroci, stari 6 do manj kot 12 let, s telesno maso od 28 kg do manj kot 35 kg:
Children aged 7-11 months received 2 primary doses followed by a booster dose in the second year of life.
Otroci, stari od 7 do 11 mesecev, so dobili 2 primarna odmerka, ki jim je sledil obnovitveni odmerek v drugem letu življenja.
Children aged between 12 and 23 months need two doses, with an interval of at least two months between doses.
Otroci, ki so stari od 12 do 23 mesecev, potrebujejo dva odmerka, med katerima mora biti vsaj dvomesečni presledek.
Children aged between 12 months and five years are given two doses with an interval of at least two months between them.
Otroci, stari od 12 mesecev do pet let, potrebujejo dva odmerka, med katerima mora biti vsaj dvomesečni presledek.
Children aged between 24 months and five years need one single dose.
Otroci, ki so stari od 24 mesecev do pet let, potrebujejo en sam odmerek.
children aged between seven months and 11 months should first receive two doses with an interval of at least one month followed by a third dose in the second year;
otroci, stari od sedem do 11 mesecev, prejmejo najprej dva odmerka, med katerima mora miniti vsaj en mesec, tretji odmerek pa morajo prejeti v drugem letu starosti;
Children aged from 2 months to < 12 years and adolescents aged from 12 to < 18 years with bodyweight < 33 kg: see Table 2.
Otroci, stari od 2. meseca do < 12 let, in mladostniki, stari od 12 do < 18 let s telesno maso < 33 kg: glejte preglednico 2.
Children aged less than 6 months
Otroci, mlajši od 6 mesecev
Children aged less than 6 months of age
Otroci, mlajši od 6 mesecev
Children aged less than 6 months of age:
Otroci, mlajši od 6 mesecev:
Children and adolescent
Otroci in mladostniki
Children and adolescent (from 3 to 17 years of age):
Otroci in mladostniki (od 3 do 17 let starosti):
Children and adolescent population: Growth and development (chronic hepatitis C)
Otroci in mladostniki: Rast in razvoj (kronični hepatitis C)
Children and adolescents
Otroci in maldostniki
Children and adolescents
Otroci in mladostnikii
Children and adolescents
Uporaba pri otrocih in mladostniki
Children and adolescents
Uporaba pri otrocih in mladostnikih
Children and adolescents (1–17 years)
Otroci in mladostniki (1–17 let)
Children and adolescents (2 years of age and above)
Otroci in mladostniki (od 2. leta dalje)
Children and adolescents (2-18 years old)
Otroci in mladostniki (stari 2-18 let)
Children and adolescents (3 months to 17 years of age)
Otroci in mladostniki (stari od 3 mesece do 17 let)
Children and adolescents (3 months to 17 years of age)
Otroci in mladostniki (stari od 3 mesecev do 17 let)
Children and adolescents (3 – 17 years of age)
Otroci in mladostniki od 3 do 17 let starosti
Children and adolescents (5-18 years): Limited data indicate that pharmacokinetics in children and adolescents dosed to steady state at 1, 7 or 12 mg/kg daily, in divided doses, are similar to those observed in adults, after adjustment for bodyweight.
Otroci in mladostniki (5 – 18 let): Omejeni podatki kažejo, da je farmakokinetika pri otrocih in mladostnikih v stanju dinamičnega ravnovesja pri odmerkih 1, 7 ali 12 mg/kg na dan v deljenih odmerkih podobna kot pri odraslih po prilagoditvi glede na telesno maso.
Children and adolescents (8 to 17 years of age)
Otroci in mladostniki (stari od 8 do 17 let)
Children and Adolescents (9-17 years)
Otroci in mladostniki (9-17 let)
Children and adolescents (< 18 years of age)
Otroci in mladostniki (< 18 let starosti)
Children and adolescents (age 0 to 18) with AIDS from birth and recurrent bacterial infections.
Otrocih in mladostniki (stari od 0 do 18 let) z AIDS-om, pridobljenim ob rojstvu, in ponavljajočimi se bakterijskimi okužbami.
Children and adolescents (age below 18 years).
Otroci in mladostniki (mlajši od 18 let).
Children and adolescents (aged 1 month to 17 years)
Otroci in mladostniki (stari 1 mesec do17 let)
Children and adolescents (aged 21 years and younger)
Otroci in mladostniki (stari 21 let in mlajši)
Children and adolescents (below 18 years of age)
Otroci in mladostniki (stari manj kot 18 let)
Children and adolescents (≥ 1 year old)
Otroci in mladostniki (≥ 1 leto)
Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV- RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrolled in two multicentre trials and received Viraferon 3 MIU/m2 3 times a week plus ribavirin 15 mg/kg per day for 1 year followed by 6 months follow-up after-treatment.
Otroci in mladostniki, stari od 3 do 16 let in s kompenziranim kroničnim hepatitisom C in merljivimi količinami HCV RNA (kar je ocenil osrednji laboratorij z uporabo raziskovalnega testa RT-PCR), so bili vključeni v dve multicentrični preskušanji in so zdravilo Viraferon prejemali v odmerku 3 mio i.e./m2 trikrat na teden skupaj z ribavirinom v odmerku 15 mg/kg na dan v času enega leta, čemur je sledilo 6
Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV- RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrolled in two multicentre trials and received Viraferon 3 MIU/m2 3 times a week plus ribavirin 15 mg/kg per day for 1 year followed by 6 months follow-up after-treatment.
Otroci in mladostniki, stari od 3 do 16 let in s kompenziranim kroničnim hepatitisom C in merljivimi količinami HCV RNA (kar je ocenil osrednji laboratorij z uporabo raziskovalnega testa RT-PCR), so bili vključeni v dve multicentrični preskušanji in so zdravilo Viraferon prejemali v odmerku 3 mio i.e./m2 trikrat na teden skupaj z ribavirinom v odmerku 15 mg/kg na dan v času enega leta, čemur je sledilo 6- mesečno spremljanje po zdravljenju.
Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV-RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrol2led in two multicentre trials and received ribavirin 15 mg/kg per day plus interferon alfa-2b 3 MIU/m 3 times a week for 1 year followed by 6 months follow-up after treatment.
Otroci in mladostniki, stari od 3 do 16 let in s kompenziranim kroničnim hepatitisom C in merljivimi količinami serumske RNA-HCV (kar je ocenil osrednji laboratorij z uporabo raziskovalnega testa RT- PCR), so bili vključeni v dve multicentrični preskušanji in so ribavirin prejemali v odmerku 15 mg/kg na dan skupaj z interferonom alfa-2b v odmerku 3 mio i.e./m2 trikrat na teden v času enega leta, čemur je sledilo 6-mesečno spremljanje po zdravljenju.
Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV-RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrolled in two multicentre trials and received ribavirin 15 mg/kg per day plus interferon alfa-2b 3 MIU/m2 3 times a week for 1 year followed by 6 months follow-up after treatment.
Otroci in mladostniki, stari od 3 do 16 let in s kompenziranim kroničnim hepatitisom C in merljivimi količinami HCV RNA (kar je ocenil osrednji laboratorij z uporabo raziskovalnega testa RT-PCR), so bili vključeni v dve multicentrični preskušanji in so ribavirin prejemali v odmerku 15 mg/kg na dan skupaj z interferonom alfa-2b v odmerku 3 mio i.e./m2 trikrat na teden v času enega leta, čemur je sledilo 6-mesečno spremljanje po zdravljenju.
Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV-RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrolled in two multicentre trials and received ribavirin 15 mg/kg per day plus interferon alfa-2b 3 MIU/m2 3 times a week for 1 year followed by 6 months follow-up after treatment.
Otroci in mladostniki, stari od 3 do 16 let in s kompenziranim kroničnim hepatitisom C in merljivimi količinami serumske RNA-HCV (kar je ocenil osrednji laboratorij z uporabo raziskovalnega testa RT- PCR), so bili vključeni v dve multicentrični preskušanji in so ribavirin prejemali v odmerku 15 mg/kg na dan skupaj z interferonom alfa-2b v odmerku 3 mio i.e./m2 trikrat na teden v času enega leta, čemur je sledilo 6-mesečno spremljanje po zdravljenju.
Children and adolescents 3 to 17 years of age with compensated chronic hepatitis C and detectable HCV-RNA were enrolled in a multicentre trial and treated with ribavirin 15 mg/kg per day plus PegIntron 60 µg/m2 once weekly for 24 or 48 weeks, based on HCV genotype and baseline viral load.
Otroke in mladostnike, stare od 3 do 17 let, s kompenziranim kroničnim hepatitisom C in merljivo HCV-RNA so vključili v multicentrično preskušanje in jih zdravili z ribavirinom 15 mg/kg na dan in zdravilom PegIntron 60 µg/m2 enkrat na teden 24 ali 48 tednov, glede na genotip HCV in virusno breme na začetku preskušanja.
Children and adolescents 3 to 17 years of age with compensated chronic hepatitis C and detectable HCV-RNA were enrolled in a multicentre trial and treated with ribavirin 15 mg/kg per day plus PegIntron 60 g/m2 once weekly for 24 or 48 weeks, based on HCV genotype and baseline viral load.
Otroke in mladostnike, stare od 3 do 17 let, s kompenziranim kroničnim hepatitisom C in merljivo HCV-RNA so vključili v multicentrično preskušanje in jih zdravili z ribavirinom 15 mg/kg na dan in zdravilom PegIntron 60 µg/m2 enkrat na teden 24 ali 48 tednov, glede na genotip HCV in virusno breme na začetku preskušanja.
Children and adolescents 3 to 17 years of age with compensated chronic hepatitis C and detectable HCV-RNA were enrolled in a multicentre trial and treated with ribavirin 15 mg/kg per day plus ViraferonPeg 60 g/m2 once weekly for 24 or 48 weeks, based on HCV genotype and baseline viral load.
Otroke in mladostnike, stare od 3 do 17 let, s kompenziranim kroničnim hepatitisom C in merljivo HCV-RNA so vključili v multicentrično preskušanje in jih zdravili z ribavirinom 15 mg/kg na dan in zdravilom ViraferonPeg 60 µg/m2 enkrat na teden 24 ali 48 tednov, glede na genotip HCV in virusno breme na začetku preskušanja.
Children and adolescents 3-17 years of age:
Otroci in mladostniki, stari od 3-17 let:
Children and adolescents 5–17 years
Otroci in mladostniki, stari od 5 do 17 let
Children and adolescents 6 months to 17 years of age
Otroci in mladostniki, stari od 6 mesecev do 17 let
Children and adolescents 6 months to 17 years of age
Otroci in mladostnikih, stari od 6 mesecev do 17 let
Children and adolescents : Axura is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Otroci in mladostniki: Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila Axura pri otrocih pod 18 let ni priporočljiva.
Children and adolescents : Memantine Merz is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Otroci in mladostniki: Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila Memantine Merz pri otrocih pod 18 let ni priporočljiva.
Children and adolescents aged 12 years or older Psoriasis
Otroci in mladostniki, stari 12 let in več
Children and adolescents aged 12 years or older Psoriasis
POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
children and adolescents aged 2 to less than 18 years who have already been treated with other HIV medicines which are no longer fully effective due to development of resistance, or have caused side effects.
otroke in mladostnike, stare 2 do manj kot 18 let, predhodno že zdravljenje z drugimi zdravili proti HIV, ki niso več polno učinkovita zaradi nastanka odpornosti ali so povzročala neželene učinke.
Children and adolescents aged 2-17 years
Otroci in mladostniki, stari od 2 do 17 let
Children and adolescents aged 6 to 17 years of age
Otroci in mladostniki, stari od 6 do 17 let
Children and adolescents aged between 12 and 17 years and weighing at least 40 kg can take the adult dose of one tablet (50 mg), once a day.
Otroci in mladostniki, stari od 12 do 17 let, ki tehtajo vsaj 40 kg, lahko jemljejo odmerek za odrasle, to je eno tableto (50 mg) enkrat na dan.
Children and Adolescents are particularly prone to develop depression when being treated with Ribavirin Teva Pharma B.V. and interferon alpha.
Otroci in mladostniki: Otroci so še posebej nagnjeni k depresiji, kadar so zdravljeni z zdravilom Ribavirin Teva Pharma B.V. in interferonom alfa.
Children and adolescents are particularly prone to develop depression when being treated with Ribavirin Teva Pharma B.V. and interferon alpha.
Uporaba pri otrocih in mladostnikih: Otroci so še posebej nagnjeni k depresiji, kadar so zdravljeni z zdravilom Ribavirin Teva Pharma B.V. in interferonom alfa.
Children and adolescents at continuous risk for acquiring Japanese encephalitis (residing in endemic areas) should receive a booster dose at month 12 after primary immunization (see section 5.1).
Otroci in mladoletniki, ki so stalno izpostavljeni nevarnosti okužbe z virusom japonskega encefalitisa (ki bivajo na endemičnih območjih), naj bi prejeli obnovitveni odmerek 12 mesecev po primarni imunizaciji (oglejte si poglavje 5.1).
Children and adolescents from 12 months to less than 18 years of age
Otroci in mladostniki, stari od 12 mesecev do manj kot 18 let
Children and adolescents from 24 months:
Otroci in mladostniki stari 24 mesecev ali več:
Children and adolescents from 3 years to < 18 years of age
Otroci in mladostniki, stari od 3 let do < 18 let starosti
Children and adolescents from 4 years of age
Otroci od 4. leta starosti in mladostniki
Children and adolescents from 6 years of age weighing 40 kg or more
Otroci od 6. leta starosti in mladostnik, ki tehtajo 40 kg ali več
Children and adolescents may experience the same side effects as adults.
Pri otrocih in mladostnikih se lahko pojavijo enaki neželeni učinki kot pri odraslih.
Children and adolescents must not take combination therapy with this medicine and alpha interferon when there is existence or history of serious nervous or mental problems such as severe depression, suicidal thoughts of suicide or attempted suicide.
Otroci in mladostniki ne smete prejemati kombiniranega zdravljenja s tem zdravilom in alfa interferonom, če ste imeli v preteklosti resne živčne ali duševne težave, na primer hudo depresijo, samomorilne misli ali poskus samomora.
Children and adolescents must not take combination therapy with this medicine and alpha interferon when there is existence or history of serious nervous or mental problems: such as severe depression, suicidal thoughts of suicide or attempted suicide
Otroci in mladostniki ne smete prejemati kombiniranega zdravljenja s tem zdravilom in alfa interferonom, če ste imeli v preteklosti resne živčne ali duševne težave, na primer hudo depresijo, samomorilne misli ali poskus samomora.
Children and adolescents should be monitored every
Otroke in mladostnike je treba spremljati na vsake
Children and adolescents should be monitored every 3 months for evidence of thyroid dysfunction (e.g.
Otroke in mladostnike morate spremljati na vsake 3 mesece glede morebitnih znakov motenj delovanja žleze ščitnice (npr.
Children and adolescents treated with Intuniv may show an increase in their BMI.
Otrokom in mladostnikom, ki se zdravijo z zdravilom Intuniv, se lahko zveča ITM.
Children and adolescents under 18 years of age receiving salicylate therapy should avoid vaccination with Pandemic influenza vaccine H5N1 MedImmune (see section 4.4).
Otroci in mladostniki, mlajši od 18 let, ki prejemajo zdravljenje s salicilati, ne smejo biti cepljeni s Cepivom proti pandemski gripi H5N1 MedImmune (glejte poglavje 4.4).
Children and adolescents under 18 years old should not take Ranexa.
Otroci in mladostniki, mlajši od 18, let ne smejo jemati zdravila Ranexa.
Children and adolescents under the age of 18 should not be given Dynastat.
Otrokom in mladostnikom, mlajšim od 18 let, se zdravila Dynastat ne sme dajati.
Children and adolescents up to 18 years of age who weigh at least 33 kg and who are able to swallow hard capsules: one 200 mg hard capsule, each day with or without food.
Za otroke in mladino do 18. leta starosti, ki tehtajo najmanj 33 kg, in ki lahko pogoltnejo trdo kapsulo: ena 200 mg trda kapsula dnevno z ali brez hrane.
Children and adolescents weighing less than 47 kg:
Otroci in mladostniki s telesno maso pod 47 kg:
Children and adolescents weighing less than 47kg:
Otroci in mladostniki, ki tehtajo manj kot 47 kg:
Children and adolescents who took infliximab for Crohn’s disease showed some differences in side effects compared with adults who took infliximab for Crohn's disease.
Neželeni učinki pri otrocih in mladostnikih, ki so prejemali infliksimab za zdravljenje Crohnove bolezni, so se nekoliko razlikovali od tistih pri odraslih, ki so prejemali infliksimab za zdravljenje Crohnove bolezni.
Children and adolescents with clinical immunodeficiency due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids.
Otroci in mladostniki s klinično imunodeficienco zaradi bolezni ali imunosupresivnega zdravljenja kot: akutne in kronične oblike levkemije; limfom; simptomatska okužba z virusom HIV; celična imunodeficienca in uporaba kortikosteroidov v visokih odmerkih.
Children and adolescents with moderate to severe active JIA, ages 6 to 17 years with an inadequate response or intolerance to at least one DMARD, which may have included biologic agents, were enrolled.
V študijo so bili vključeni otroci in mladostniki z zmernim do hudim aktivnim juvenilnim idiopatskim artritisom, stari od 6 do 17 let, z nezadostnim odzivom ali intoleranco na zdravljenje vsaj z enim od imunomodulirajočih protirevmatičnih zdravil, ki so lahko vključevala tudi biološka zdravila.
Children and adolescents with PNH or aHUS and who are 40 kg weight and over are treated with the adult dosing.
Otroci in mladostniki s PNH in z aHUS in tisti s telesno maso 40 kg ali več se zdravijo z odmerki za odrasle.
Children and adolescents with PNH or aHUS and who are under 40 kg weight require a lower dose based on how much they weigh.
Otroci in mladostniki s PNH in z aHUS in tisti s telesno maso manj kot 40 kg potrebujejo manjše odmerke, ki so izračunani na osnovi njihove telesne mase.
Children and adolescents with the Acquired Immune Deficiency Syndrome (AIDS), it can be used to prevent troublesome infections.
Pri otrocih in mladostnikih s sindromom pridobljene imunske pomanjkljivosti (AIDS) se lahko uporablja za preprečevanje težavnih okužb.
Children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye’s syndrome with salicylates and wild-type influenza infection.
Otroci in mladostniki stari manj kot 18 let, ki se zdravijo s salicilatom zaradi povezave z Reyevim sindromom pri uporabi salicilatov in okužbo z gripo virusa divjega tipa.
Children and adolescents – Chronic Hepatitis C
Otroci in mladostniki – Kronični hepatitis C
Children and adolescents:
Otroci in mladostniki
Children and adolescents: Axura is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Otroci in mladostniki: Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila Axura pri otrocih pod 18 let ni priporočljiva.
Children and adolescents: if you have had serious nervous or mental problems, such as severe depression or thoughts of suicide.
Otroci in mladostniki: če ste kdaj imeli resno bolezen živčevja ali duševne težave, kot so huda depresija ali samomorilne misli.
Children and adolescents: if you have had serious nervous or mental problems, such as severe depression or thoughts of suicide.
Otroci in mladostniki: če ste kdaj imeli resno živčno ali duševno bolezen, npr. hudo depresijoali samomorilne misli.
Children and adolescents: Memantine Merz is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Otroci in mladostniki: Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila Memantine Merz pri otrocih pod 18 let ni priporočljiva.
Children and adolescents: Multiple-dose pharmacokinetic properties for Viraferon injection and ribavirin capsules in children and adolescents with chronic hepatitis C, between 5 and 16 years of age, are summarized in Table 6.
Otroci in mladostniki: Farmakokinetične lastnosti pri večkratnem odmerjanju zdravila Viraferon injekcije in kapsul ribavirina pri otrocih in mladostnikih s kroničnim hepatitisom C v starosti od 5 do 16 let so
Children and adolescents: Multiple-dose pharmacokinetic properties for Viraferon injection and ribavirin capsules in children and adolescents with chronic hepatitis C, between 5 and 16 years of age, are summarized in Table 6.
Otroci in mladostniki: Farmakokinetične lastnosti pri večkratnem odmerjanju zdravila Viraferon injekcije in kapsul ribavirina pri otrocih in mladostnikih s kroničnim hepatitisom C v starosti od 5 do 16 let so povzete v Preglednici 6.
Children and adolescents: Nemdatine is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Otroci in mladostniki: Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila Nemdatine pri otrocih in mladostnikih mlajših od 18 let ni priporočljiva.
Children and adolescents: not applicable
Otroci in mladostniki: ne pride v poštev
Children and adolescents: ≥ 11 g/dl (females); ≥ 12 g/dl (males)
Otroci in mladostniki ≥ 11 g/dl (ženske); ≥ 12 g/dl (moški)
Children and Adolescents: ≥ 11 g/dl (females); ≥ 12 g/dl (males)
Otroci in mladostniki ≥11 g/dl (ženske); ≥12 g/dl (moški)
Children and adolscents (2 years of age and above)
Otroci in mladostniki (od 2. leta dalje)
Children and adults taking Flixabi may have an increased risk of developing lymphoma or another cancer.
Otroci in odrasli, ki prejemajo zdravilo Flixabi, imajo lahko povečano tveganje za pojav limfoma ali katere druge vrste raka.
Children and adults taking Inflectra may have an increased risk of developing lymphoma or another cancer.
Otroci in odrasli, ki jemljejo zdravilo Inflectra, imajo lahko povečano tveganje za pojav limfoma ali katere druge vrste raka.
Children and adults taking Remicade may have an increased risk of developing lymphoma or another cancer.
Otroci in odrasli, ki prejemajo zdravilo Remicade, imajo lahko povečano tveganje za pojav limfoma ali katere druge vrste raka.
Children and adults taking Remsima may have an increased risk of developing lymphoma or another cancer.
Otroci in odrasli, ki prejemajo zdravilo Remsima, imajo lahko povečano tveganje za pojav limfoma ali katere druge vrste raka.
Children and teenagers
Otroci in mladostniki
Children and young people
Otroci in mladostniki